Accéder au contenu
MilliporeSigma
  • Targeting of the E3 ubiquitin-protein ligase HUWE1 impairs DNA repair capacity and tumor growth in preclinical multiple myeloma models.

Targeting of the E3 ubiquitin-protein ligase HUWE1 impairs DNA repair capacity and tumor growth in preclinical multiple myeloma models.

Scientific reports (2020-10-30)
Viktoria Kunz, Kathryn S Bommert, Jessica Kruk, Daniel Schwinning, Manik Chatterjee, Thorsten Stühmer, Ralf Bargou, Kurt Bommert
RÉSUMÉ

Experimental evidence suggests that ubiquitin-protein ligases regulate a number of cellular processes involved in tumorigenesis. We analysed the role of the E3 ubiquitin-protein ligase HUWE1 for pathobiology of multiple myeloma (MM), a still incurable blood cancer. mRNA expression analysis indicates an increase in HUWE1 expression levels correlated with advanced stages of myeloma. Pharmacologic as well as RNAi-mediated HUWE1 inhibition caused anti-proliferative effects in MM cell lines in vitro and in an MM1.S xenotransplantation mouse model. Cell cycle analysis upon HUWE1 inhibition revealed decreased S phase cell fractions. Analyses of potential HUWE1-dependent molecular functions did not show involvement in MYC-dependent gene regulation. However, HUWE1 depleted MM cells displayed increased DNA tail length by comet assay, as well as changes in the levels of DNA damage response mediators such as pBRCA1, DNA-polymerase β, γH2AX and Mcl-1. Our finding that HUWE1 might thus be involved in endogenous DNA repair is further supported by strongly enhanced apoptotic effects of the DNA-damaging agent melphalan in HUWE1 depleted cells in vitro and in vivo. These data suggest that HUWE1 might contribute to tumour growth by endogenous repair of DNA, and could therefore potentially be exploitable in future treatment developments.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Tampon RIPA
Sigma-Aldrich
Bleu de trypan solution, 0.4%, liquid, sterile-filtered, suitable for cell culture
Sigma-Aldrich
Melphalan, powder
Sigma-Aldrich
BI8622, ≥98% (HPLC)
Melphalan, British Pharmacopoeia (BP) Reference Standard